Ticker

XWELL (NASDAQ: XWEL - Get Free Report) and HealthEquity (NASDAQ: HQY - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitability, analyst recommendations, valuation, earnings and dividends. Analyst Recommendations This is a summary of current ratings and

XWELL (NASDAQ: XWEL - Get Free Report) and Organon and Co. (NYSE: OGN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Volatility and Risk XWELL has a beta

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- XWELL, Inc. (Nasdaq: XWEL) ("XWELL" or the "Company"), a leading provider of wellness solutions for people on the go, today announced financial results for the year ended December 31, 2025.

XWELL, Inc. (NASDAQ: XWEL - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 527,181 shares, a decrease of 78.7% from the February 26th total of 2,476,054 shares. Based on an average daily volume of 1,692,311 shares, the

XWELL (NASDAQ: XWEL - Get Free Report) and iSpecimen (NASDAQ: ISPC - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Valuation and Earnings This table compares XWELL and iSpecimen"s